The mechanism of gluten intolerance in coeliac disease is unknown but may be due to an abnormal immunological reaction to wheat proteins.1 Patients with untreated coeliac disease have an increased infiltration of lymphocytes in the small intestinal mucosa.2 Local antibody-mediated immune reactions have been demonstrated in the mucosa of both children and adults with coeliac disease after a gluten challenge3 and cell-mediated immunity to gluten, as measured by blastogenesis, has been found in peripheral blood lymphocytes in the presence of both gluten fraction III4 and a subfraction thereof.5
The leucocyte migration inhibition factor assay (LMIF assay) has also been used to study cellmediated immune reactions to gluten fractions in patients with coeliac disease.6 Antigen induced inhibition of leucocyte migration has been widely accepted as an in vitro correlate of cellular immunity in man.7 Cell migration is thought to be inhibited by lymphokines which are the products of antigenlymphocyte interaction.8 The extent of migration inhibition depends both on lymphocyte sensitisation and the responsiveness of leucocytes to lymphokines.9 Using an LMIF assay 13% of untreated coeliac patients and 54% of treated patients were sensitised to gluten fraction III10 and 37.5% and Received for publication 2 June 1981 80% untreated and treated groups respectively to an alpha-gliadin fraction. 1 1 Clausen12 used cell-free supernatants to assay for LMIF production. This is a more sensitive and easily controllable system than the direct or one step method. The supernatants are obtained from peripheral blood mononuclear cells (PBMC) cultured in the presence of the antigen to be examined and tested against normal indicator cells. The specific reaction of antigen recognition by sensitised PBMC with the subsequent release of lymphokine is the first step and the assay of the lymphokine is the second.
In this study, alpha-gliadin, a wheat protein shown to be toxic to coeliac patients,13 was prepared using an ion-exchange chromatographic technique. The specificity of the response to this antigen was assessed using both the direct and indirect LMIF assays.
Methods

SUBJECTS
Twenty-three patients with adult coeliac disease, of whom 15 were on gluten free diets and eight were untreated, were studied. All had subtotal or severe partial villous atrophy on jejunal biopsy and a clinical response to a gluten free diet of at least one year's duration in the treated patients, and response to the diet after testing in the untreated group. All the coeliac patients on gluten free diets attended the coeliac clinic regularly on a three month basis and were interviewed by a dietician. If any patient appeared not be be adhering to the diet, he was excluded from the study.
Control groups included 15 healthy laboratory staff and 15 patients with inflammatory bowel disease of whom seven had Crohn's disease and six had ulcerative colitis. None of the former control group was biopsied and of the latter group all had confirmatory histology of the lesion and six had small intestinal histology which excluded coeliac disease. In the remainder no clinical or laboratory feature pointed to anything other than inflammatory bowel disease.
DIRECT LMIF ASSAY
The direct assay was carried out according to Haeney and Asquith.11 The results are expressed as migration indices (MI) which were derived as follows:
Mean (of 3) migration area in antigen containing medium MI Mean (of 3) migration area in medium alone
Heparinised venous blood diluted 1: 2 in Hank's balanced salt solution (HBSS, Gibco Biocult), was layered onto a Ficoll-paque gradient (Pharmacia, Uppsala). After centrifugation at 1200 RPM for 35 minutes the mononuclear cells (PBMC) found at the interface were removed and washed twice with HBSS. The cells were finally resuspended at a concentration of 1 x 106 cells/ml of medium in RPMI (Gibco Biocult) containing 10% fetal calf serum and 10 mN Hepes's buffer, pH 7.3. Aliquots containing 1 ml of cell suspension were dispensed into upright plastic culture tubes with or without 1 pg/ml alpha-gliadin. Cultures were incubated for 72 hours at 37TC. in a 5% CO2 water-saturated atmosphere. At the end of the incubation period, the cell suspensions were centrifuged at 2000 rpm. The supernatants were harvested and diluted 1:2 with fresh RPMI. The unstimulated culture supernatants were reconstituted with appropriate concentrations of antigen, before testing for the presence of LMIF. Leucocyte suspensions from healthy donors served as indicators for LMIF activity in the supernatants. The technique used was similar to that of the direct LMIF assay.
PREPARATION OF ANTIGEN
Gliadin was prepared according to Eterman et al.14 using milled Irish flour. The wheat protein was further processed using a modification of an ionexchange chromatographic technique.15 A column 15 x 5 cm was packed with carboxy-methylcellulose, Whatman, CM52, and buffered to pH 4-2 with eluant (0.005M sodium acetate buffer). The flow rate was adjusted to 150 ml/hour. One gram of lyophylised gliadin resuspended in 100 ml of buffer was applied to the column. A stepped gradient of sodium chloride in the sodium acetate buffer was used to elute the different fractions. Six fractions were obtained. These were concentrated using a rotary film evaporator, dialysed extensively to remove the salt, and then lyophylised. The eluate obtained with a sodium chloride concentration of 0.09M corresponded to the alpha gliadin used by other workers (Hekkens, personal communication) .
It was found that 1 mg/ml of medium gave optimum results in the direct LMIF assay and 1 ig/ml in the indirect assay.
STATISTICS
As the data were normally distributed, Student's t test for unpaired data was used to analyse the results.
Results
DIRECT LMIF ASSAY (Fig. 1) The mean MI of leucocytes isolated from treated coeliac patients when tested in the presence of alpha gliadin was 0.42+0.12 SD, from normal individuals was 0.99+0.08 SD, and from patients with noncoeliac disorders was 1-02+0-10 SD. The difference between the coeliac subjects and the control groups was significant (P <0 01).
Leucocytes isolated from eight untreated coeliac patients had a mean MI of 0-73 +0 27 SD (P >0 05, when compared with either of the control groups); four were within the normal range and four showed significant inhibition.
INDIRECT LMIF ASSAY (Fig. 2 ) PBMC isolated from treated or untreated patients, cultured in the presence of alpha gliadin released LMIF into the culture medium. These supernatants when compared with the control groups significantly inhibited the migration of normal leucocytes at the 1% level. The mean MI for treated coeliacs was 0.67+0-12 SD and for untreated coeliac patients 0-64+0-10 SD; the difference between the treated and untreated groups was not significant. PBMC isolated from treated or untreated coeliac patients and cultured in the absence of alpha-gliadin did not produce any detectable LMIF (mean MI 1.00+0.08 and 1-00 + 0-03 respectively). The differences with and without alpha-gliadin for both the treated and untreated groups were highly significant (P <0 001). group.bmj.com on July 22, 2015 -Published by http://gut.bmj.com/ Downloaded from whether alpha gliadin was (mean MI 0.97+0.05) or was not (mean MI 0.99 + 005) in the culture medium. The mean MI of patients with other gastrointestinal disorders was 1.04+0 09 SD with and 0 95 + 0 10 SD without alpha-gliadin. The differences between the control groups, with and without alphagliadin, were not significant.
Discussion
This study confirms the specificity of the response elicited by alpha-gliadin when used as an antigen for direct LMIF assays in treated coeliac patients as shown by others.6 11 Other preparations of wheat protein and casein do not appear to elicit such a specific response (unpublished data when biopsy specimens obtained from the small intestine of untreated coeliac patients are cultured with alpha-gliadin they secrete a factor into the culture medium which inhibits the migration of normal leucocytes. They propose that a local cell-mediated response to gliadin causes the villous atrophy and crypt hyperplasia which characterises the coeliac mucosal lesion. This study shows that mononuclear cells obtained from the peripheral blood of untreated coeliac patients also produce a substance which inhibits normal leucocyte migration.
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